Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 6 studies | 26% ± 6% | |
epithelial cell | 6 studies | 23% ± 5% | |
adipocyte | 4 studies | 20% ± 6% | |
GABAergic neuron | 4 studies | 36% ± 12% | |
astrocyte | 4 studies | 32% ± 17% | |
oligodendrocyte | 4 studies | 28% ± 12% | |
microglial cell | 3 studies | 21% ± 7% | |
glutamatergic neuron | 3 studies | 52% ± 8% | |
oligodendrocyte precursor cell | 3 studies | 27% ± 13% | |
endothelial cell of lymphatic vessel | 3 studies | 21% ± 4% | |
fibroblast | 3 studies | 20% ± 3% | |
macrophage | 3 studies | 18% ± 2% | |
transit amplifying cell | 3 studies | 34% ± 14% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 4 studies | 43% ± 11% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 1218.45 | 1445 / 1445 | 100% | 11.09 | 183 / 183 |
stomach | 100% | 922.13 | 359 / 359 | 100% | 8.18 | 286 / 286 |
lung | 100% | 1107.05 | 578 / 578 | 100% | 6.27 | 1154 / 1155 |
intestine | 100% | 1289.47 | 966 / 966 | 100% | 7.13 | 526 / 527 |
breast | 100% | 1286.56 | 459 / 459 | 100% | 6.45 | 1114 / 1118 |
bladder | 100% | 1270.29 | 21 / 21 | 100% | 5.17 | 502 / 504 |
ovary | 100% | 1454.34 | 180 / 180 | 100% | 6.21 | 428 / 430 |
pancreas | 100% | 705.91 | 327 / 328 | 99% | 3.83 | 177 / 178 |
uterus | 100% | 1466.24 | 170 / 170 | 99% | 4.54 | 455 / 459 |
prostate | 100% | 1160.04 | 245 / 245 | 99% | 4.45 | 496 / 502 |
brain | 99% | 843.04 | 2608 / 2642 | 100% | 4.00 | 705 / 705 |
thymus | 100% | 1113.45 | 653 / 653 | 98% | 3.43 | 593 / 605 |
skin | 100% | 1772.39 | 1809 / 1809 | 98% | 6.07 | 461 / 472 |
kidney | 100% | 821.10 | 89 / 89 | 96% | 3.83 | 861 / 901 |
adrenal gland | 100% | 1018.77 | 258 / 258 | 87% | 2.36 | 200 / 230 |
liver | 100% | 538.65 | 226 / 226 | 81% | 2.01 | 329 / 406 |
adipose | 100% | 1245.06 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 1079.78 | 1335 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 5.77 | 29 / 29 |
muscle | 100% | 1078.91 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 1370.53 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 5.42 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 1.66 | 1 / 1 |
heart | 96% | 703.77 | 830 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 93% | 3.16 | 74 / 80 |
peripheral blood | 65% | 1221.68 | 603 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0007091 | Biological process | metaphase/anaphase transition of mitotic cell cycle |
GO_0031145 | Biological process | anaphase-promoting complex-dependent catabolic process |
GO_0070936 | Biological process | protein K48-linked ubiquitination |
GO_0070979 | Biological process | protein K11-linked ubiquitination |
GO_0051301 | Biological process | cell division |
GO_0051445 | Biological process | regulation of meiotic cell cycle |
GO_0007346 | Biological process | regulation of mitotic cell cycle |
GO_0005680 | Cellular component | anaphase-promoting complex |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005829 | Cellular component | cytosol |
GO_0060090 | Molecular function | molecular adaptor activity |
Gene name | ANAPC1 |
Protein name | Anaphase-promoting complex subunit 1 (APC1) (Cyclosome subunit 1) (Mitotic checkpoint regulator) (Testis-specific gene 24 protein) Anaphase promoting complex subunit 1 |
Synonyms | TSG24 |
Description | FUNCTION: Component of the anaphase promoting complex/cyclosome (APC/C), a cell cycle-regulated E3 ubiquitin ligase that controls progression through mitosis and the G1 phase of the cell cycle. The APC/C complex acts by mediating ubiquitination and subsequent degradation of target proteins: it mainly mediates the formation of 'Lys-11'-linked polyubiquitin chains and, to a lower extent, the formation of 'Lys-48'- and 'Lys-63'-linked polyubiquitin chains. . |
Accessions | ENST00000341068.8 ENST00000643447.1 ENST00000628342.1 ENST00000427997.5 F8WAS1 Q9H1A4 A0A2R8YF63 H0Y564 ENST00000451367.3 |